世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

筋萎縮性側索硬化症治療薬の世界市場成長(現状と展望)2024-2030年


Global Amyotrophic Lateral Sclerosis Drugs Market Growth (Status and Outlook) 2024-2030

筋萎縮性側索硬化症(ALS)はルー・ゲーリッグ病またはシャルコー病とも呼ばれ、神経細胞が徐々に破壊され死滅する神経疾患である。 90%から95%の症例では原因が不明である。残りの5-10%は両親からの遺伝であ... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
LP Information
LPインフォメーション
2024年5月24日 US$3,660
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
113 英語

日本語のページは自動翻訳を利用し作成しています。


 

サマリー

筋萎縮性側索硬化症(ALS)はルー・ゲーリッグ病またはシャルコー病とも呼ばれ、神経細胞が徐々に破壊され死滅する神経疾患である。
90%から95%の症例では原因が不明である。残りの5-10%は両親からの遺伝である。これらの遺伝的ケースの約半数は、2つの特定の遺伝子のうちの1つが原因である。基本的な機序は、上下両方の運動ニューロンの損傷である。診断は、患者の徴候と症状に基づいて行われ、他の潜在的な原因を除外するために検査が行われる。
筋萎縮性側索硬化症治療薬の世界市場規模は、2023年の2億9350万米ドルから2030年には3億4610万米ドルに成長すると予測されており、2024年から2030年までの年平均成長率は2.4%と予測されています。
LPI(LPインフォメーション)の最新調査レポート「筋萎縮性側索硬化症治療薬産業予測」は、過去の売上高と2023年の筋萎縮性側索硬化症治療薬の世界総売上高に注目し、2024年から2030年までの筋萎縮性側索硬化症治療薬の予測売上高を地域別・市場分野別に包括的に分析しています。筋萎縮性側索硬化症治療薬の売上高を地域別、市場分野別、サブセクター別に分類し、世界の筋萎縮性側索硬化症治療薬産業の詳細な分析を百万米ドル単位で提供しています。
本インサイトレポートでは、世界の筋萎縮性側索硬化症治療薬の状況を包括的に分析し、製品区分、企業形成、売上高、市場シェア、最新動向、M&A活動に関する主要動向を明らかにしています。また本レポートでは、筋萎縮性側索硬化症治療薬のポートフォリオと能力、市場参入戦略、市場での地位、地理的な足跡に焦点を当て、世界の主要企業の戦略を分析し、加速する世界の筋萎縮性側索硬化症治療薬市場におけるこれらの企業の独自の地位をより深く理解しています。
本インサイトレポートでは、筋萎縮性側索硬化症治療薬の世界的な見通しを形成している主要な市場動向、促進要因、影響要因を評価し、タイプ別、用途別、地域別、市場規模別に分類して予測を行い、新たな機会のポケットを浮き彫りにします。何百ものボトムアップの質的・量的市場インプットに基づいた透明性の高い手法により、本調査予測は筋萎縮性側索硬化症治療薬の世界における現状と将来の軌跡について非常にニュアンスの異なる見解を提供します。
世界の医薬品市場は2022年に1,475億ドルに達し、今後6年間のCAGRは5%で成長する。医薬品市場には化学医薬品と生物学的製剤が含まれる。生物製剤は2022年に3810億ドルになると予想されている。これに対し、化学医薬品市場は2018年の1,050億米ドルから2022年には1,090億米ドルに増加すると推定されている。医薬品市場の要因としては、医療需要の増加、技術の進歩、慢性疾患の有病率の上昇、医薬品製造分野の開発に対する民間&政府機関からの資金提供の増加、医薬品の研究開発活動の活発化などが挙げられる。しかし、厳しい規制、研究開発費の高騰、特許切れといった課題にも直面している。企業は、市場での競争力を維持し、必要としている患者に確実に製品を届けるために、継続的に技術革新を行い、こうした課題に適応していく必要がある。さらに、COVID-19の大流行はワクチン開発とサプライチェーン管理の重要性を浮き彫りにし、製薬企業が新たな公衆衛生のニーズに機敏に対応する必要性をさらに強調しています。
本レポートでは、筋萎縮性側索硬化症治療薬市場の製品タイプ別、用途別、主要企業別、主要地域別および国別の包括的な概要、市場シェア、成長機会を紹介する。
タイプ別セグメント
リルゾール
エダラボン(ラジカヴァ)
CoQ10
ブチルフタリド
その他
用途別セグメント
病院薬局
小売薬局
オンライン薬局
本レポートは地域別にも市場を分割しています:
南北アメリカ
アメリカ
カナダ
メキシコ
ブラジル
APAC
中国
日本
韓国
東南アジア
インド
オーストラリア
ヨーロッパ
ドイツ
フランス
英国
イタリア
ロシア
中東・アフリカ
エジプト
南アフリカ
イスラエル
トルコ
GCC諸国
以下の企業は、主要な専門家から収集した情報、および企業のカバレッジ、製品ポートフォリオ、市場浸透度の分析に基づいて選択されています。
サノフィ
田辺三菱製薬
マイラン
アポテックス
グレマーク・ジェネリック
サンファーマ
コヴィス・ファーマ
ルナン・ファーマ
CSPCファーマシューティカル
アセンド・ラボラトリーズ
EISAI


ページTOPに戻る


目次

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Amyotrophic Lateral Sclerosis Drugs Market Size 2019-2030
2.1.2 Amyotrophic Lateral Sclerosis Drugs Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Amyotrophic Lateral Sclerosis Drugs Segment by Type
2.2.1 Riluzole
2.2.2 Edaravone (Radicava)
2.2.3 CoQ10
2.2.4 Butylphthalide
2.2.5 Others
2.3 Amyotrophic Lateral Sclerosis Drugs Market Size by Type
2.3.1 Amyotrophic Lateral Sclerosis Drugs Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Amyotrophic Lateral Sclerosis Drugs Market Size Market Share by Type (2019-2024)
2.4 Amyotrophic Lateral Sclerosis Drugs Segment by Application
2.4.1 Hospital Pharmacies
2.4.2 Retail Pharmacies
2.4.3 Online Pharmacies
2.5 Amyotrophic Lateral Sclerosis Drugs Market Size by Application
2.5.1 Amyotrophic Lateral Sclerosis Drugs Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Amyotrophic Lateral Sclerosis Drugs Market Size Market Share by Application (2019-2024)
3 Amyotrophic Lateral Sclerosis Drugs Market Size by Player
3.1 Amyotrophic Lateral Sclerosis Drugs Market Size Market Share by Players
3.1.1 Global Amyotrophic Lateral Sclerosis Drugs Revenue by Players (2019-2024)
3.1.2 Global Amyotrophic Lateral Sclerosis Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Amyotrophic Lateral Sclerosis Drugs Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Amyotrophic Lateral Sclerosis Drugs by Regions
4.1 Amyotrophic Lateral Sclerosis Drugs Market Size by Regions (2019-2024)
4.2 Americas Amyotrophic Lateral Sclerosis Drugs Market Size Growth (2019-2024)
4.3 APAC Amyotrophic Lateral Sclerosis Drugs Market Size Growth (2019-2024)
4.4 Europe Amyotrophic Lateral Sclerosis Drugs Market Size Growth (2019-2024)
4.5 Middle East & Africa Amyotrophic Lateral Sclerosis Drugs Market Size Growth (2019-2024)
5 Americas
5.1 Americas Amyotrophic Lateral Sclerosis Drugs Market Size by Country (2019-2024)
5.2 Americas Amyotrophic Lateral Sclerosis Drugs Market Size by Type (2019-2024)
5.3 Americas Amyotrophic Lateral Sclerosis Drugs Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Amyotrophic Lateral Sclerosis Drugs Market Size by Region (2019-2024)
6.2 APAC Amyotrophic Lateral Sclerosis Drugs Market Size by Type (2019-2024)
6.3 APAC Amyotrophic Lateral Sclerosis Drugs Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Amyotrophic Lateral Sclerosis Drugs by Country (2019-2024)
7.2 Europe Amyotrophic Lateral Sclerosis Drugs Market Size by Type (2019-2024)
7.3 Europe Amyotrophic Lateral Sclerosis Drugs Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Amyotrophic Lateral Sclerosis Drugs by Region (2019-2024)
8.2 Middle East & Africa Amyotrophic Lateral Sclerosis Drugs Market Size by Type (2019-2024)
8.3 Middle East & Africa Amyotrophic Lateral Sclerosis Drugs Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.1 Global Amyotrophic Lateral Sclerosis Drugs Forecast by Regions (2025-2030)
10.1.1 Global Amyotrophic Lateral Sclerosis Drugs Forecast by Regions (2025-2030)
10.1.2 Americas Amyotrophic Lateral Sclerosis Drugs Forecast
10.1.3 APAC Amyotrophic Lateral Sclerosis Drugs Forecast
10.1.4 Europe Amyotrophic Lateral Sclerosis Drugs Forecast
10.1.5 Middle East & Africa Amyotrophic Lateral Sclerosis Drugs Forecast
10.2 Americas Amyotrophic Lateral Sclerosis Drugs Forecast by Country (2025-2030)
10.2.1 United States Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.2.2 Canada Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.2.3 Mexico Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.2.4 Brazil Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.3 APAC Amyotrophic Lateral Sclerosis Drugs Forecast by Region (2025-2030)
10.3.1 China Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.3.2 Japan Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.3.3 Korea Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.3.4 Southeast Asia Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.3.5 India Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.3.6 Australia Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.4 Europe Amyotrophic Lateral Sclerosis Drugs Forecast by Country (2025-2030)
10.4.1 Germany Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.4.2 France Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.4.3 UK Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.4.4 Italy Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.4.5 Russia Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.5 Middle East & Africa Amyotrophic Lateral Sclerosis Drugs Forecast by Region (2025-2030)
10.5.1 Egypt Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.5.2 South Africa Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.5.3 Israel Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.5.4 Turkey Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.5.5 GCC Countries Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.6 Global Amyotrophic Lateral Sclerosis Drugs Forecast by Type (2025-2030)
10.7 Global Amyotrophic Lateral Sclerosis Drugs Forecast by Application (2025-2030)

11 Key Players Analysis
11.1 Sanofi
11.1.1 Sanofi Company Information
11.1.2 Sanofi Amyotrophic Lateral Sclerosis Drugs Product Offered
11.1.3 Sanofi Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Sanofi Main Business Overview
11.1.5 Sanofi Latest Developments
11.2 Mitsubishi Tanabe Pharma
11.2.1 Mitsubishi Tanabe Pharma Company Information
11.2.2 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis Drugs Product Offered
11.2.3 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Mitsubishi Tanabe Pharma Main Business Overview
11.2.5 Mitsubishi Tanabe Pharma Latest Developments
11.3 Mylan
11.3.1 Mylan Company Information
11.3.2 Mylan Amyotrophic Lateral Sclerosis Drugs Product Offered
11.3.3 Mylan Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Mylan Main Business Overview
11.3.5 Mylan Latest Developments
11.4 Apotex
11.4.1 Apotex Company Information
11.4.2 Apotex Amyotrophic Lateral Sclerosis Drugs Product Offered
11.4.3 Apotex Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Apotex Main Business Overview
11.4.5 Apotex Latest Developments
11.5 Glemark Generics
11.5.1 Glemark Generics Company Information
11.5.2 Glemark Generics Amyotrophic Lateral Sclerosis Drugs Product Offered
11.5.3 Glemark Generics Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Glemark Generics Main Business Overview
11.5.5 Glemark Generics Latest Developments
11.6 Sun Pharma
11.6.1 Sun Pharma Company Information
11.6.2 Sun Pharma Amyotrophic Lateral Sclerosis Drugs Product Offered
11.6.3 Sun Pharma Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Sun Pharma Main Business Overview
11.6.5 Sun Pharma Latest Developments
11.7 Covis Pharma
11.7.1 Covis Pharma Company Information
11.7.2 Covis Pharma Amyotrophic Lateral Sclerosis Drugs Product Offered
11.7.3 Covis Pharma Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Covis Pharma Main Business Overview
11.7.5 Covis Pharma Latest Developments
11.8 Lunan Pharma
11.8.1 Lunan Pharma Company Information
11.8.2 Lunan Pharma Amyotrophic Lateral Sclerosis Drugs Product Offered
11.8.3 Lunan Pharma Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Lunan Pharma Main Business Overview
11.8.5 Lunan Pharma Latest Developments
11.9 CSPC Pharmaceutical
11.9.1 CSPC Pharmaceutical Company Information
11.9.2 CSPC Pharmaceutical Amyotrophic Lateral Sclerosis Drugs Product Offered
11.9.3 CSPC Pharmaceutical Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 CSPC Pharmaceutical Main Business Overview
11.9.5 CSPC Pharmaceutical Latest Developments
11.10 Ascend Laboratories
11.10.1 Ascend Laboratories Company Information
11.10.2 Ascend Laboratories Amyotrophic Lateral Sclerosis Drugs Product Offered
11.10.3 Ascend Laboratories Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Ascend Laboratories Main Business Overview
11.10.5 Ascend Laboratories Latest Developments
11.11 EISAI
11.11.1 EISAI Company Information
11.11.2 EISAI Amyotrophic Lateral Sclerosis Drugs Product Offered
11.11.3 EISAI Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.11.4 EISAI Main Business Overview
11.11.5 EISAI Latest Developments
12 Research Findings and Conclusion

 

ページTOPに戻る


 

Summary

Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.
The cause is not known in 90% to 95% of cases. The remaining 5–10% of cases are inherited from a person's parents. About half of these genetic cases are due to one of two specific genes. The underlying mechanism involves damage to both upper and lower motor neurons. The diagnosis is based on a person's signs and symptoms, with testing done to rule out other potential causes.
The global Amyotrophic Lateral Sclerosis Drugs market size is projected to grow from US$ 293.5 million in 2023 to US$ 346.1 million in 2030; it is expected to grow at a CAGR of 2.4% from 2024 to 2030.
LPI (LP Information)' newest research report, the “Amyotrophic Lateral Sclerosis Drugs Industry Forecast” looks at past sales and reviews total world Amyotrophic Lateral Sclerosis Drugs sales in 2023, providing a comprehensive analysis by region and market sector of projected Amyotrophic Lateral Sclerosis Drugs sales for 2024 through 2030. With Amyotrophic Lateral Sclerosis Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Amyotrophic Lateral Sclerosis Drugs industry.
This Insight Report provides a comprehensive analysis of the global Amyotrophic Lateral Sclerosis Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Amyotrophic Lateral Sclerosis Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Amyotrophic Lateral Sclerosis Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Amyotrophic Lateral Sclerosis Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Amyotrophic Lateral Sclerosis Drugs.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report presents a comprehensive overview, market shares, and growth opportunities of Amyotrophic Lateral Sclerosis Drugs market by product type, application, key players and key regions and countries.
Segmentation by type
Riluzole
Edaravone (Radicava)
CoQ10
Butylphthalide
Others
Segmentation by application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Sanofi
Mitsubishi Tanabe Pharma
Mylan
Apotex
Glemark Generics
Sun Pharma
Covis Pharma
Lunan Pharma
CSPC Pharmaceutical
Ascend Laboratories
EISAI



ページTOPに戻る


Table of Contents

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Amyotrophic Lateral Sclerosis Drugs Market Size 2019-2030
2.1.2 Amyotrophic Lateral Sclerosis Drugs Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Amyotrophic Lateral Sclerosis Drugs Segment by Type
2.2.1 Riluzole
2.2.2 Edaravone (Radicava)
2.2.3 CoQ10
2.2.4 Butylphthalide
2.2.5 Others
2.3 Amyotrophic Lateral Sclerosis Drugs Market Size by Type
2.3.1 Amyotrophic Lateral Sclerosis Drugs Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Amyotrophic Lateral Sclerosis Drugs Market Size Market Share by Type (2019-2024)
2.4 Amyotrophic Lateral Sclerosis Drugs Segment by Application
2.4.1 Hospital Pharmacies
2.4.2 Retail Pharmacies
2.4.3 Online Pharmacies
2.5 Amyotrophic Lateral Sclerosis Drugs Market Size by Application
2.5.1 Amyotrophic Lateral Sclerosis Drugs Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Amyotrophic Lateral Sclerosis Drugs Market Size Market Share by Application (2019-2024)
3 Amyotrophic Lateral Sclerosis Drugs Market Size by Player
3.1 Amyotrophic Lateral Sclerosis Drugs Market Size Market Share by Players
3.1.1 Global Amyotrophic Lateral Sclerosis Drugs Revenue by Players (2019-2024)
3.1.2 Global Amyotrophic Lateral Sclerosis Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Amyotrophic Lateral Sclerosis Drugs Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Amyotrophic Lateral Sclerosis Drugs by Regions
4.1 Amyotrophic Lateral Sclerosis Drugs Market Size by Regions (2019-2024)
4.2 Americas Amyotrophic Lateral Sclerosis Drugs Market Size Growth (2019-2024)
4.3 APAC Amyotrophic Lateral Sclerosis Drugs Market Size Growth (2019-2024)
4.4 Europe Amyotrophic Lateral Sclerosis Drugs Market Size Growth (2019-2024)
4.5 Middle East & Africa Amyotrophic Lateral Sclerosis Drugs Market Size Growth (2019-2024)
5 Americas
5.1 Americas Amyotrophic Lateral Sclerosis Drugs Market Size by Country (2019-2024)
5.2 Americas Amyotrophic Lateral Sclerosis Drugs Market Size by Type (2019-2024)
5.3 Americas Amyotrophic Lateral Sclerosis Drugs Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Amyotrophic Lateral Sclerosis Drugs Market Size by Region (2019-2024)
6.2 APAC Amyotrophic Lateral Sclerosis Drugs Market Size by Type (2019-2024)
6.3 APAC Amyotrophic Lateral Sclerosis Drugs Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Amyotrophic Lateral Sclerosis Drugs by Country (2019-2024)
7.2 Europe Amyotrophic Lateral Sclerosis Drugs Market Size by Type (2019-2024)
7.3 Europe Amyotrophic Lateral Sclerosis Drugs Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Amyotrophic Lateral Sclerosis Drugs by Region (2019-2024)
8.2 Middle East & Africa Amyotrophic Lateral Sclerosis Drugs Market Size by Type (2019-2024)
8.3 Middle East & Africa Amyotrophic Lateral Sclerosis Drugs Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.1 Global Amyotrophic Lateral Sclerosis Drugs Forecast by Regions (2025-2030)
10.1.1 Global Amyotrophic Lateral Sclerosis Drugs Forecast by Regions (2025-2030)
10.1.2 Americas Amyotrophic Lateral Sclerosis Drugs Forecast
10.1.3 APAC Amyotrophic Lateral Sclerosis Drugs Forecast
10.1.4 Europe Amyotrophic Lateral Sclerosis Drugs Forecast
10.1.5 Middle East & Africa Amyotrophic Lateral Sclerosis Drugs Forecast
10.2 Americas Amyotrophic Lateral Sclerosis Drugs Forecast by Country (2025-2030)
10.2.1 United States Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.2.2 Canada Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.2.3 Mexico Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.2.4 Brazil Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.3 APAC Amyotrophic Lateral Sclerosis Drugs Forecast by Region (2025-2030)
10.3.1 China Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.3.2 Japan Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.3.3 Korea Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.3.4 Southeast Asia Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.3.5 India Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.3.6 Australia Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.4 Europe Amyotrophic Lateral Sclerosis Drugs Forecast by Country (2025-2030)
10.4.1 Germany Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.4.2 France Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.4.3 UK Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.4.4 Italy Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.4.5 Russia Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.5 Middle East & Africa Amyotrophic Lateral Sclerosis Drugs Forecast by Region (2025-2030)
10.5.1 Egypt Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.5.2 South Africa Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.5.3 Israel Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.5.4 Turkey Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.5.5 GCC Countries Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.6 Global Amyotrophic Lateral Sclerosis Drugs Forecast by Type (2025-2030)
10.7 Global Amyotrophic Lateral Sclerosis Drugs Forecast by Application (2025-2030)

11 Key Players Analysis
11.1 Sanofi
11.1.1 Sanofi Company Information
11.1.2 Sanofi Amyotrophic Lateral Sclerosis Drugs Product Offered
11.1.3 Sanofi Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Sanofi Main Business Overview
11.1.5 Sanofi Latest Developments
11.2 Mitsubishi Tanabe Pharma
11.2.1 Mitsubishi Tanabe Pharma Company Information
11.2.2 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis Drugs Product Offered
11.2.3 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Mitsubishi Tanabe Pharma Main Business Overview
11.2.5 Mitsubishi Tanabe Pharma Latest Developments
11.3 Mylan
11.3.1 Mylan Company Information
11.3.2 Mylan Amyotrophic Lateral Sclerosis Drugs Product Offered
11.3.3 Mylan Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Mylan Main Business Overview
11.3.5 Mylan Latest Developments
11.4 Apotex
11.4.1 Apotex Company Information
11.4.2 Apotex Amyotrophic Lateral Sclerosis Drugs Product Offered
11.4.3 Apotex Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Apotex Main Business Overview
11.4.5 Apotex Latest Developments
11.5 Glemark Generics
11.5.1 Glemark Generics Company Information
11.5.2 Glemark Generics Amyotrophic Lateral Sclerosis Drugs Product Offered
11.5.3 Glemark Generics Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Glemark Generics Main Business Overview
11.5.5 Glemark Generics Latest Developments
11.6 Sun Pharma
11.6.1 Sun Pharma Company Information
11.6.2 Sun Pharma Amyotrophic Lateral Sclerosis Drugs Product Offered
11.6.3 Sun Pharma Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Sun Pharma Main Business Overview
11.6.5 Sun Pharma Latest Developments
11.7 Covis Pharma
11.7.1 Covis Pharma Company Information
11.7.2 Covis Pharma Amyotrophic Lateral Sclerosis Drugs Product Offered
11.7.3 Covis Pharma Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Covis Pharma Main Business Overview
11.7.5 Covis Pharma Latest Developments
11.8 Lunan Pharma
11.8.1 Lunan Pharma Company Information
11.8.2 Lunan Pharma Amyotrophic Lateral Sclerosis Drugs Product Offered
11.8.3 Lunan Pharma Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Lunan Pharma Main Business Overview
11.8.5 Lunan Pharma Latest Developments
11.9 CSPC Pharmaceutical
11.9.1 CSPC Pharmaceutical Company Information
11.9.2 CSPC Pharmaceutical Amyotrophic Lateral Sclerosis Drugs Product Offered
11.9.3 CSPC Pharmaceutical Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 CSPC Pharmaceutical Main Business Overview
11.9.5 CSPC Pharmaceutical Latest Developments
11.10 Ascend Laboratories
11.10.1 Ascend Laboratories Company Information
11.10.2 Ascend Laboratories Amyotrophic Lateral Sclerosis Drugs Product Offered
11.10.3 Ascend Laboratories Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Ascend Laboratories Main Business Overview
11.10.5 Ascend Laboratories Latest Developments
11.11 EISAI
11.11.1 EISAI Company Information
11.11.2 EISAI Amyotrophic Lateral Sclerosis Drugs Product Offered
11.11.3 EISAI Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.11.4 EISAI Main Business Overview
11.11.5 EISAI Latest Developments
12 Research Findings and Conclusion

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります


よくあるご質問


LP Information社はどのような調査会社ですか?


LP Informationは通信、エネルギー、医薬をはじめとする広範な市場の調査とレポート出版を行っている調査会社です。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/05 10:26

153.43 円

167.28 円

201.52 円

ページTOPに戻る